Your browser doesn't support javascript.
loading
[Grey zones on diabetes in cardiovascular disease. Expert opinion]. / Grey zones sul diabete mellito in ambito cardiologico. Opinioni degli esperti.
Trevisan, Roberto; Grosu, Aurelia; Avogaro, Angelo; Agostoni, Piergiuseppe; Ceconi, Claudio; Genovese, Stefano; Bossi, Antonio; Pitì, Antonio; Senni, Michele; Maggioni, Aldo Pietro.
Afiliação
  • Trevisan R; U.O.C. Malattie Endocrine 1-Diabetologia, Dipartimento di Medicina, ASST Papa Giovanni XXIII, Bergamo.
  • Grosu A; U.O.C. Cardiologia 1, Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo.
  • Avogaro A; U.O. Malattie del Metabolismo, Dipartimento di Medicina, Università degli Studi, Padova.
  • Agostoni P; Dipartimento Cardiovascolare, IRCCS Centro Cardiologico Monzino, Milano.
  • Ceconi C; U.O. Cardiologia, ASST del Garda, Desenzano del Garda (BS).
  • Genovese S; Unità di Diabetologia, Endocrinologia e Malattie Metaboliche, IRCCS Centro Cardiologico Monzino, Milano.
  • Bossi A; U.O.C. Malattie Endocrine e Centro Regionale per il Diabete Mellito, Dipartimento di Medicina, ASST Bergamo Ovest, Treviglio (BG).
  • Pitì A; U.O.C. Cardiologia, Dipartimento Cardiovascolare, ASST Bergamo Est, Seriate (BG).
  • Senni M; U.O.C. Cardiologia 1, Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo.
  • Maggioni AP; Centro Studi ANMCO, Fondazione per il Tuo cuore - Heart Care Foundation Onlus, Firenze.
G Ital Cardiol (Rome) ; 21(12): 916-922, 2020 Dec.
Article em It | MEDLINE | ID: mdl-33231210
ABSTRACT
Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies in diabetes mellitus and cardiovascular disease. The first topic concerns the appropriateness of second level cardiovascular screening of the entire population of diabetic patients. The second gap in evidence concerns the validity of a target of glycated hemoglobin considering the last trials. The work has also been implemented with the evidences deriving from important randomized studies published after the date of the Conference.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiologia / Doenças Cardiovasculares / Diabetes Mellitus Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Humans Idioma: It Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cardiologia / Doenças Cardiovasculares / Diabetes Mellitus Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Humans Idioma: It Ano de publicação: 2020 Tipo de documento: Article